KINIKSA PHARMACEUTICALS INTERNATIONAL PLC 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Richard S. Levy

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Richard S. Levy”): 48,474,904 for, 1,182,085 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,618,066 for, 592,300 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Sanj K. Patel

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Sanj K. Patel”): 48,345,527 for, 1,315,700 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,615,101 for, 595,265 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class I Directors to serve until the 2028 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Thomas R. Malley

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Thomas R. Malley”): 40,767,926 for, 8,874,763 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 82% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 8,452,178 for, 1,758,188 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Barry D. Quart

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Barry D. Quart”): 48,477,460 for, 1,179,591 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,635,960 for, 574,406 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: G. Bradley Cole

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: G. Bradley Cole”): 48,537,052 for, 1,118,892 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,635,960 for, 574,406 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class II Directors to serve until the 2026 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Stephen R. Biggar

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Stephen R. Biggar”): 34,345,226 for, 15,310,717 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 4,877,232 for, 5,333,134 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Felix J. Baker, Ph.D.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Felix J. Baker, Ph.D.”): 37,399,001 for, 12,262,083 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 75% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 5,938,303 for, 4,272,063 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Kimberly J. Popovits

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Kimberly J. Popovits”): 48,444,882 for, 1,212,399 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,635,960 for, 574,406 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: M. Cantey Boyd

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: M. Cantey Boyd”): 49,525,094 for, 131,795 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 10,210,366 for, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: Election of Class III Directors to serve until the 2027 Annual General Meeting of Shareholders, and until their respective successors have been appointed or until their earlier resignation or vacation of office in accordance with Kiniksa's articles of association: Tracey L. McCain

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“Elect Director: Tracey L. McCain”): 48,523,788 for, 1,119,195 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 66 asset managers below reported 9,635,960 for, 574,406 against, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To authorize the Board of Directors, generally and unconditionally for the purpose of section 551 of the UK Companies Act 2006 (the "Companies Act") to allot shares in the Company or to grant rights to subscribe for or to convert any security into shares in the company ("Rights") up to a maximum aggregate nominal amount of $6,976.33, which represents approximately 35% of the issued ordinary share capital of the Company on the record date for the 2025 Annual General Meeting of Shareholders. This authority shall expire (unless previously renewed, varied or revoked) on June 2, 2030, but we may at any time before the expiration of this authority make an offer or agreement which would or might require shares to be allotted, or Rights to be granted, pursuant to this authority after its expiration, and the Board of Directors may allot shares or grant Rights in pursuance of that offer or agreement as if the authority conferred by this resolution had not expired. The authority granted by this resolution shall replace all of our existing authorities to allot any shares and to grant Rights previously granted in connection with the adoption of the Articles in June 2024, but without prejudice to any allotment of shares or grant of Rights already made or agreed or offered to be made pursuant to such authorities.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“11. To authorize the Company's board of directors to allot shares or convert securities into shares with a total nominal amount capped at $6,976.33, which represents approximately 35% of the Company's issued ordinary sha”): 41,191,486 for, 11,185,289 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 7,863,029 for, 2,352,655 against.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Description as filed by funds: Subject to the passing of Proposal No. 11, to empower the Board of Directors generally pursuant to section 570(1) and section 573 of the Companies Act to allot equity securities (as defined in section 560 of the Companies Act) for cash pursuant to the general authority conferred on them by Proposal No. 11 as if section 561(1) of the Companies Act did not apply to that allotment. This power (a) shall be limited to the allotment of equity securities up to a maximum aggregate of $6,976.33; (b) will expire (unless previously renewed, varied or revoked) on June 2, 2030, but we may at any time before the expiration of this power make an offer or agreement which would or might require equity securities to be allotted after that expiry and the Board of Directors may allot equity securities pursuant to any of those offers or agreements as if the power had not expired; and (c) will apply in relation to a sale of shares which is an allotment of equity securities by virtue of section 560(3) of the Companies Act as if in the first paragraph of this proposal the words "pursuant to the general authority conferred on them by Proposal No. 11" were omitted. For purposes of this resolution, references to the allotment of equity securities shall be interpreted in accordance with section 560 of the Companies Act. This resolution replaces all unexercised powers previously granted to the Board of Directors, pursuant to the adoption of the Articles in June 2024, to allot equity securities as if section 561 of the Companies Act did not apply but shall be without prejudice to any allotment of equity securities already made or agreed or agreed to be made pursuant to such authorities.

The 45 asset managers below reported 5,260,853 for, 2,298,025 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

Description as filed by funds: TO RECEIVE THE COMPANY'S UK STATUTORY ANNUAL ACCOUNTS AND REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“7. To receive the Company's UK statutory annual account and report for the period ended December 31, 2024”): 51,839,847 for, 1,442 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 10,202,423 for, 13,261 abstained.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Description as filed by funds: To authorize the Board of Directors to conduct a transaction with the Company's wholly-owned subsidiary, Kiniksa Pharmaceuticals, Ltd. ("Kiniksa Bermuda"), whereby the Company will redeem the preference shares previously issued to Kiniksa Bermuda through the capitalization of the Company's merger reserve account and subsequently cancelling the merger reserve bonus share issued as part of such capitalization via a court-approved process, thus creating distributable reserves to be utilized to redeem such preference shares and thereby allowing for the liquidation of Kiniksa Bermuda.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“13. To authorize the Company to conduct a transaction with Kiniksa Pharmaceuticals, Ltd., the Company's wholly-owned subsidiary, whereby the Company will redeem preference shares previously issued to it through the capit”): 52,354,709 for, 23,158 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 10,210,374 for, 13,261 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“10. To approve, on an advisory non-binding basis, the compensation of the Company's named executive officers”): 49,107,201 for, 550,666 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 10,182,101 for, 41,471 against, 13,261 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 175 managers: 22,042,402 for, 366,994 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE, ON AN ADVISORY (NON-BINDING) BASIS, THE COMPANY'S UK STATUTORY DIRECTORS' ANNUAL REMUNERATION REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“8. To approve, on an advisory non-binding basis, the Company's UK Statutory Directors' Annual Remuneration Report for the period ended December 31, 2024”): 49,232,977 for, 427,203 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 58 managers: 9,700,872 for, 41,471 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 35 managers: 8,185,834 for, 49,081 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO APPROVE THE COMPANY'S UK STATUTORY DIRECTORS' REMUNERATION POLICY.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“9. To approve the Company's UK Statutory Directors' Remuneration Policy”): 49,456,271 for, 199,712 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 67 managers: 10,202,434 for, 21,138 against, 13,261 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 4 managers: 1,931,215 for, 6,768 against.

Description as filed by funds: To authorize the Company's Board of Directors, through its Audit Committee, the authority to determine PwC's remuneration in its capacity as our UK statutory auditors until the close of our next Annual General Meeting of Shareholders.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“6. To authorize the Company's board of directors, through its audit committee, to determine PwC's remuneration in its capacity as the Company's UK statutory auditors until the close of its next Annual Meeting of Sharehol”): 52,357,935 for, 8,139 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 67 asset managers below reported 10,223,572 for, 13,261 abstained.

Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.

Description as filed by funds: To approve the appointment of PricewaterhouseCoopers LLP ("PwC") as the Company's UK statutory auditors until the close of our next Annual General Meeting of Shareholders.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“4. To approve the appointment of PricewaterhouseCoopers LLP (" PwC ") as the Company's UK statutory auditors until the close of the Company's next Annual Meeting”): 52,360,413 for, 18,079 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify PricewaterhouseCoopers LLP as Auditors” (2 managers, 7,943 for).

The 66 asset managers below reported 10,210,366 for, 13,261 abstained.

Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.

Description as filed by funds: To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2025.

KINIKSA PHARMACEUTICALS INTERNATIONAL PLC’s own tally for this item (“5. To ratify the appointment of PwC as the Company's US independent registered public accounting firm for the fiscal year ending December 31, 2025”): 52,359,608 for, 19,322 against, per its Form 8-K filed June 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 10,202,423 for, 13,261 abstained.

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.